Rutgers is leading a clinical trial assessing the combination of nitazoxanide, ribavirin and hydroxychloroquine to treat people 21 or older who are infected with SARS-CoV-2 and are asymptomatic or mildly symptomatic. The trial is being conducted with Synavir Corporation, a global health company that works with academia, industry and government to develop combination treatments for new viral infections. The trial — called Triple Combination Antiviral Coronavirus Therapy (TriACT) — seeks to determine whether treating people who test positive for coronavirus but who do not have symptoms or have mild symptoms with this combination will reduce the amount of virus and their chances of getting sick. To read the full story.
Home / News / Researchers are investigating a potential treatment for people recently diagnosed with SARS-CoV-2 who have no or mild symptoms
Recent Posts
- Study Finds Widespread Exposure to Hormone-Disrupting Chemical During Pregnancy.
- Community-Based Programs in Senior Centers May Lower Health Care Use and Costs for People with Dementia
- New NJACTS Publication
- How Rutgers Health and Vaccine Equity Education Coalition Ambassadors at the Boys & Girls Club of Newark Are Promoting Vaccine Equity.
- Center for Environmental Exposures and Disease 7th Annual Environmental Health and Justice Summit 10/18, 9am-4pm
Categories
- Community (2,020)
- Covid (975)
- CTO Events (3)
- News (2,570)
- Pilots (20)